Viaskin™ Peanut’s Long-Term Phase III Updates and What the FDA Has to Say About Them

Viaskin™ Peanut’s Long-Term Phase III Updates and What the FDA Has to Say About Them

Source: 
BioSpace
snippet: 

BioSpace spoke with Mohideen and Todd Green, MD, pediatric allergist and VP of Clinical Development and Medical Affairs at DBV, about their recently published Phase III open-label extension trial data, touching on the FDA’s recent decision to deny approval of Viaskin™ Peanut in its current form and what the next steps are. Rose Joachim, Ph.D., a Senior Healthcare Analyst at GlobalData, also provided insights into how Viaskin™ Peanut fits into the landscape of peanut immunotherapy.